Taiga Biotechnologiesincis A Clinical Stagebiotechnology Company Focused On Harnessing Thepower Of Theimmunesystem To Fight Solid Tumors And Infectious Diseaseand On Improving Blood Stem Cell Transplantation What Wedo Aecfor Healthy Immunesystemsour Immunotherapy Programs Temporarily Boost Theimmunesystem So That It Functions Better To Fight Both Solid Tumors And Infectious Diseaseaecfor Compromised Immunesystemsour Regenerativemedicineprogram Generates A Newhealthy Immunesystem 1 Our Lead Cell Based Immunotherapy Product Candidatetbx 400Uses A Patient S Own Immunecells To Help Fight Against Solid Tumors And Infectious Diseasetbx 400 Is An Autologous Cell Product Madefrom Peripheral Blood Mononuclear Cells That Aretreated Ex Vivo With Our Fusion Protein And Then Delivered Intravenously Back To Thepatient Thefollowing Dayour Cell Based Immunotherapy Technology Has Several Advantages Over Current Immunotherapy Approachesaecwedo Not Need To Expand T Cells In Thelaboratory To Generateenough T Cells For Treatment Aecwedo Not Limit Theresponseto Thetumor Based By Engineering Thespecificity Of Thet Cell Aecwedo Not Requiregenetic Modification Of Thet Cells To Enableantitumor Activity 2Our Bonemarrow Engraftment Enhancerbmeeprogram Is Developing A First Lineproducttbx 2400To Enhancetheengraftment Of Hematopoietic Stem And Progenitor Cells During An Allogeneic Hematopoietic Stem Cell Transplanthsct Our Bmeegoal Is To Increasethechanceof Long Term Survival Of A Hsct Recipient By Aecincreasing Theprobability Of A Successful Engraftment Aecincreasing Therateof Reconstitution Of Matureand Functional Lymphocytesandaecmanaging Thecomplications Associated With Hsct
